HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 机器翻译
🆙#ESMO26 口头报告论文 II：#LCSM 转移瘤 🔥Dalmelitinib 联合 Aumolertinib 对比含铂化疗，用于接受 EGFR TKI 后出现 MET 扩增的晚期 NSCLC 患者：一项随机、3 期研究 🎙️Ziming Li 医生 🔢2615O 🎯达到主要终点：IRC-PFS 6.2 vs 4.4个月（HR 0.601，p<0.001；n=314）；ORR 59.6% vs 38.6%；OS HR 0.840（数据尚不成熟，46.8%交叉）；≥3级 TEAEs 50.0% vs 51.0% ☑️NCT06110663 🔗 https://t.co/M4ccE0ikXo @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
热度 1 · 1 赞 · 0 回复 · 0 转发
会议摘要
NCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy读摘要原文 →来源：HHorinouchi · x.com